Clinical Trials /

Trial of Combination of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

NCT02279394

Description:

This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.

Related Conditions:
  • Multiple Myeloma
Recruiting Status:

Active, not recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Trial of Combination of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
  • Official Title: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Clinical Trial IDs

  • ORG STUDY ID: 14-338
  • NCT ID: NCT02279394

Conditions

  • Smoldering Myeloma
  • Smoldering Multiple Myeloma

Interventions

DrugSynonymsArms
ElotuzumabHuLuc63
LenalidomideREVLIMID
DexamethasoneDecadron

Purpose

This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.

Detailed Description

      This research study is a Phase II clinical trial, which tests the effectiveness of the
      investigational drugs elotuzumab, lenalidomide and dexamethasone in smoldering multiple
      myeloma. Recent research studies have shown that early treatment of smoldering multiple
      myeloma may delay or prevent the progression to active multiple myeloma. The purpose of this
      research study is to learn whether the combination of elotuzumab, lenalidomide and
      dexamethasone works in treating smoldering multiple myeloma.
    

Trial Arms

NameTypeDescriptionInterventions

Eligibility Criteria

        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Must have smoldering myeloma with high risk markers based on the Mayo OR the Spanish
             criteria as described below

          -  >10% plasma cells in the bone marrow and any one or more of the following:

               -  Serum M protein of 3 g/dL or greater

               -  IgA SMM

               -  Immunoparesis with reduction of two uninvolved immunoglobulin isotypes

               -  Serum involved/uninvolved free light chain ratio ≥8 (but less than 100)

               -  Progressive increase in M protein level (Evolving type of SMM)†

               -  Bone marrow clonal plasma cells 50-60%

               -  Abnormal plasma cell immunophenotype (≥95% of bone marrow plasma cells are
                  clonal) and reduction of one or more uninvolved immunoglobulin isotypes

               -  t (4;14) or del 17p or 1q gain

               -  Increased circulating plasma cells

               -  MRI with diffuse abnormalities or 1 focal lesion

               -  PET-CT with focal lesion with increased uptake without underlying osteolytic bone
                  destruction † Increase in serum monoclonal protein by ≥25% on two successive
                  evaluations within a 6 month period

          -  No evidence of CRAB (see below for details) criteria or new criteria of active
             multiple myeloma which including the following:

               -  Increased calcium levels (corrected serum calcium >0.25 mmol/dL above the upper
                  limit of normal or >.275 mmol/dL)

               -  Renal insufficiency (attributable to myeloma)

               -  Anemia (Hb 2g/dL below the lower limit of normal or <10g/dL)

               -  Bone lesions (lytic lesions or generalized osteoporosis with compression
                  fractures)

               -  No evidence of the following new criteria for active MM including the following:
                  Bone marrow plasma cells ≥ 60%, Serum involved/uninvolved FLC ratio ≥100, and MRI
                  with more than one focal lesion

                    -  Participants with CRAB criteria that are attributable to conditions other
                       than the disease under study may be eligible

          -  ECOG Performance Status (PS) 0, 1, or 2 (Appendix A)

          -  The following laboratory values obtained ≤ 14 days prior to registration:

               -  ANC ≥1000/µL

               -  PLT ≥ 50,000/µL

               -  Total bilirubin ≤ 2.0 mg/dL (If total is elevated check direct and if normal
                  patient is eligible.)

               -  AST ≤ 3 x institutional upper limit of normal (ULN)

               -  ALT ≤ 3 x institutional upper limit of normal (ULN)

               -  Estimated creatinine clearance ≥ 60mL/min or a creatinine ≤ 2.2 mg/dL

          -  Voluntary written informed consent before performance of any study-related procedure
             not part of normal medical care, with the understanding that consent may be withdrawn
             by the subject at any time without prejudice to future medical care

          -  Females of childbearing potential* must have a negative serum or urine pregnancy test

          -  Men must agree to use a latex condom during sexual contact with a female of
             childbearing potential even if they have had a successful vasectomy

          -  Ability to understand and the willingness to sign a written informed consent.

          -  Exclusion Criteria:

          -  Symptomatic Multiple Myeloma or any evidence of CRAB criteria including the new
             criteria for overt myeloma. Any prior therapy for active Myeloma should also be
             excluded. Prior therapy for smoldering myeloma is not an exclusion criteria.
             Bisphosphonates are not excluded

          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
             considered investigational. Prior therapy with bisphosphonate is allowed. Prior
             radiation therapy to a solitary plasmacytoma is allowed. Prior clinical trials for
             smoldering MM or MGUS are allowed as long as the last therapy was at least 2 months
             prior and there was no improvement in M spike

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study

          -  Diagnosed or treated for another malignancy within 2 years of enrollment, with the
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy

          -  Uncontrolled intercurrent illness

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to elotuzumab or lenalidomide

          -  Known seropositive for or active viral infection with human immunodeficiency virus,
             hepatitis B virus or hepatitis C virus. Patients who are seropositive because of
             hepatitis B virus vaccine are eligible
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Proportion of patients who are progression free at 2 years
Time Frame:2 Years
Safety Issue:
Description:Time from protocol therapy initiation to progression to symptomatic myeloma

Secondary Outcome Measures

Measure:Response rate
Time Frame:2 Years
Safety Issue:
Description:Response rate based on the IMWG criteria
Measure:Safety of the combination therapy
Time Frame:4 years
Safety Issue:
Description:safety of the combination of Elotuzumab, lenalidomide+/- dexamethasone
Measure:Time to progression
Time Frame:4 years
Safety Issue:
Description:Time from initiation of therapy to progression defined by the IMWG criteria.
Measure:Overall survival
Time Frame:2 Years
Safety Issue:
Description:Time from initiation of therapy to death

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Active, not recruiting
Lead Sponsor:Dana-Farber Cancer Institute

Trial Keywords

  • Smoldering myeloma
  • Smoldering Multiple Myeloma

Last Updated